67 results on '"Castaman G"'
Search Results
2. Non-Compartment and compartmental pharmacokinetics, efficacy, and safety of Kedrion FIX concentrate
3. Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery
4. Phase 1, single‐dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia
5. An international collaborative study to compare different von Willebrand factor glycoprotein Ib binding activity assays: the COMPASS‐VWF study
6. PB1263 Third Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol in Patients with Hemophilia A Treated Every 5 or Every 7 Days: Results from the Real-World HEM-POWR Study
7. PB0854 Could Gynecologists Contribute to an Increased Diagnosis of von Willebrand Disease among Women with Heavy Menstrual Bleeding?
8. PB0811 Natural Variants of von Willebrand Factor R1205 Associated with Type 1 von Willebrand Disease: In-Silico Docking Models and Energetics of the Interactions with the Macrophagic Scavenger Receptor LRP1
9. PB0650 Safety and Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Pediatric Patients with Hemophilia B: A Review of Results from Phase 3 Trial Studies
10. PB0642 Determinants of the Bleeding Phenotype in Persons with Non-Severe Hemophilia
11. OC 59.3 Pooled Safety Results from the Multidose Explorer Studies of Concizumab in Patients with Haemophilia
12. OC 52.5 Phase 3 HOPE-B Trial of Etranacogene Dezaparvovec in Severe/Moderately Severe Hemophilia B: A Post Hoc Responder Analysis of Participants Who Received Full Dose and Responded to Treatment
13. OC 24.1 Effect of the Type of F9 Mutation on the Pharmacokinetic Profile of Patients with Hemophilia B Treated with Extended Half-Life FIX Concentrates
14. Inhibitor development and mortality in non‐severe hemophilia A
15. No evidence for a direct effect of von Willebrand factor's ABH blood group antigens on von Willebrand factor clearance
16. TREATMENT SATISFACTION AND JOINT HEALTH OUTCOMES WITHIN A REAL-WORLD HAEMOPHILIA B POPULATION: THE ADELPHI DISEASE SPECIFIC PROGRAMMESURVEY
17. LARGE DELETIONS IN THE F8 GENE PREDICT IMMUNE TOLERANCE INDUCTION FAILURE IN PEOPLE WITH SEVERE HEMOPHILIA A
18. GENETIC AND NON-GENETIC DETERMINANTS OF SUCCESSFUL IMMUNE TOLERANCE INDUCTION IN PEOPLE WITH SEVERE HEMOPHILIA A
19. Bleeders, bleeding rates, and bleeding score
20. Deep intronic variations may cause mild hemophilia A
21. Prospective evaluation of the clinical utility of quantitative bleeding severity assessment in patients referred for hemostatic evaluation
22. Alterations of mRNA processing and stability as a pathogenic mechanism in von Willebrand factor quantitative deficiencies
23. Homozygous type 2N R854W von Willebrand factor is poorly secreted and causes a severe von Willebrand disease phenotype
24. von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels
25. Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD
26. Pharmacokinetics and safety of fibrinogen concentrate
27. Molecular and phenotypic determinants of the response to desmopressin in adult patients with mild hemophilia A
28. Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study
29. Reduced von Willebrand factor survival in von Willebrand disease: pathophysiologic and clinical relevance
30. PCR191 Assessing Quality of Care in Haemophilia Using a Value-Based Healthcare Approach
31. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM‐1VWD)
32. How to estimate bleeding risk in mild bleeding disorders
33. von Willebrand factor/factor VIII concentrate (Haemate® P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery
34. A common 253‐kb deletion involving VWF and TMEM16B in German and Italian patients with severe von Willebrand disease type 3
35. Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM‐1VWD)
36. Association of protein S p.Pro667Pro dimorphism with plasma protein S levels in normal individuals and patients with inherited protein S deficiency
37. Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study
38. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM‐1 VWD)
39. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD
40. Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective study comparing patients with single (R1205H) and double (R1205H‐M740I) defect
41. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study
42. Cysteine-mutations in von Willebrand factor associated with increased clearance
43. EE120 Real-World Utilisation of Damoctocog Alfa Pegol in Adults With Haemophilia A: Second Interim Analysis of the HEM-POWR Observational Study
44. Dimerization and multimerization defects of von Willebrand factor due to mutated cysteine residues
45. Coinheritance of the HR2 Haplotype in the Factor V Gene Confers an Increased Risk of Venous Thromboembolism to Carriers of Factor V R506Q (Factor V Leiden)
46. PRO53 Economic IMPACT of Emicizumab Prophylaxis for Hemophilia a with and without Inhibitors
47. PRO40 Cost-Consequence Analysis of Emicizumab Prophylaxis for Severe Hemophilia a Patients without Inhibitors
48. PRO28 EMICIZUMAB PROPHYLAXIS IN HAEMOPHILIA A PATIENTS WITH INHIBITORS: A COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS
49. The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH
50. Different bleeding risk in type 2A and 2M von Willebrand disease: a 2‐year prospective study in 107 patients: a reply to a rebuttal
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.